Share price of Bengaluru-based biotechnology firm, Biocon Ltd, rose 3.27 per cent to Rs 341.50 at the end of Tuesday's trading session at the Bombay Stock Exchange.
This despite the company's stated stand of no possible deal with Pfizer in the near future.
The company's share price touched a 52-weeks high on Monday on speculation that the global drug major, Pfizer, may buy stake or strike a marketing deal with the company.
However, it has been strongly denied by Biocon.
"We don't want to comment on speculation," a company spokesperson said.
